Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies ...
A recent study suggests mRNA vaccines can make some tumours more responsive to immunotherapy, lowering the risk of death ...
As the availability of post-market real-world evidence expands, more attention to its promise, limitations, and oversight in ...
Agreement Lonza Expands Dual-Payload ADC Technology Offering Through Exclusive Access to Qurient’s CDK7 Inhibitors 12.10.2026 / 14:00 CET/CEST Basel, Switzerland and Seongnam, Korea, 12 October 2026 – ...
There are a variety of treatments available for IBS, including lifestyle changes, gut-directed mental health therapies, ...
This Week's Pharma News] Shionogi's 315.6 Billion Yen Acquisition, Ono Pharmaceutical's IgG Degrader Licensing, Asahi Kasei's ...
Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis ...
A vote taken by the sound of applause rang out during an early morning session at (AAO) 2026 annual meeting, where 2 experts discussed the pros and cons of using complement inhibitors to treat ...
Checkpoint inhibitors can only amplify an antitumor immune response that already exists, which is why immunologically “cold” ...
Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.
A new review maps the structural diversity of snake venom metalloproteinases and surveys a growing arsenal of plant compounds ...
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results